Physician profile
Daniela White
NPI 1174504583
$24,043.92
in general payments reported to CMS, 2019-2025
45 companies · $3,342 in 2025
The $3,342 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,081 · 2020: $2,536 · 2021: $3,620 · 2022: $3,265 · 2023: $2,943 · 2024: $2,257 · 2025: $3,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,342 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,342.46 |
| Education | $199.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,297.84 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $2,882.06 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Abbvie INC. | $2,107.55 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,479.15 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,301.15 | 2019-2022 | |
| Lundbeck LLC | $1,236.19 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,182.15 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Supernus Pharmaceuticals, INC. | $1,097.18 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, Lp | $1,053.06 | 2019-2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $943.56 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $762.20 | 2019-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $573.93 | 2019-2024 | Fanapt |
| Corium, LLC | $570.02 | 2021-2025 | Azstarys |
| Bausch Health US, LLC | $547.64 | 2019-2024 | Aplenzin |
| Allergan, INC. | $492.59 | 2019-2020 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $445.30 | 2019-2025 | Ingrezza |
| Tris Pharma INC | $414.51 | 2019-2023 | Dyanavel Xr |
| Alkermes, INC. | $394.91 | 2021-2025 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $392.44 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $370.60 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $347.77 | 2022-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $296.73 | 2023-2025 | Loreev Xr |
| Neuronetics, INC. | $263.22 | 2019-2025 | Neurostar Tms Therapy System |
| Eisai INC. | $222.53 | 2020-2022 | |
| Livanova USA, INC. | $175.33 | 2021-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Shire North American Group INC | $125.74 | 2019 | |
| Noven Therapeutics, LLC | $123.12 | 2022-2025 | Xelstrym, Secuado |
| Medtronic, INC. | $121.59 | 2022 | |
| Vertical Pharmaceuticals, LLC | $109.55 | 2019-2025 | Relexxii |
| Arbor Pharmaceuticals, INC. | $106.66 | 2019-2020 | |
| Adlon Therapeutics L.P. | $104.72 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $66.05 | 2023-2024 | Quviviq |
| Sage Therapeutics, LLC | $54.18 | 2020-2021 | |
| Tempus Ai, INC | $45.89 | 2025 | Tempus Pixel |
| Owp Pharmaceuticals, INC. | $45.49 | 2020-2021 | |
| Indivior INC. | $39.15 | 2022-2023 | Perseris |
| Validus Pharmaceuticals LLC | $36.33 | 2023-2025 | Equetro, Equetro, Raldesy |
| Janssen Scientific Affairs, LLC | $35.22 | 2019 | |
| Merck Sharp & Dohme LLC | $32.88 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.51 | 2025 | Rejoyn |
| Brainsway USA INC | $31.89 | 2019 | |
| Avanir Pharmaceuticals, INC. | $30.64 | 2019 | |
| Collegium Pharmaceutical, INC. | $21.02 | 2025 | Jornay Pm |
| Aytu Biopharma, INC. | $17.98 | 2021 | |
| Currax Pharmaceuticals LLC | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.